Published • loading... • Updated
Lilly to sell obesity drugs directly on Hims & Hers site
The deal gives Lilly broader access to self-pay patients as Hims & Hers adds Zepbound and Foundayo at prices matching LillyDirect.
- On Friday, Eli Lilly struck a deal allowing telehealth firm Hims & Hers to sell obesity drugs Zepbound and Foundayo directly on its platform, matching LillyDirect self-pay prices of $299 and $149 respectively.
- Lilly USA President Ilya Yuffa noted that current site navigation is not 'fully straightforward,' warning that friction points increase the 'chance of abandonment' for 40% to 45% of Zepbound sales through self-pay channels.
- This move positions Lilly on equal footing with Danish rival Novo Nordisk, which has sold Wegovy and Ozempic on the platform since March, with prices starting at $149 for the pill and $199 for the injector pen.
- Bolstered by booming demand, Lilly raised its full-year revenue forecast by $5 billion last week, reflecting a $1.2 trillion market valuation, while Hims & Hers agreed not to sell compounded or knockoff versions of Lilly medications.
- Analysts anticipate potential gains for Hims & Hers next year as employers re-evaluate weight-loss drug coverage to cut costs, building on Lilly's April launch of oral Foundayo, which followed Novo's Wegovy pill debut by three months.
Insights by Ground AI
7 Articles
7 Articles
Coverage Details
Total News Sources7
Leaning Left0Leaning Right1Center4Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
R 20%
Factuality
To view factuality data please Upgrade to Premium
